Plasma cell leukaemia and other aggressive plasma cell malignancies

British Journal of Haematology

Volumn 150, Issue 4, 2010, Pages 418-427

  Sher, Taimur ^a   Miller, Kena C ^a   Deeb, George ^a   Lee, Kelvin ^a   Chanan Khan, Asher ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

bortezomib; extramedullary plasmacytoma; lenalidomide and thalidomide; multiple myeloma; plasma cell leukaemia

Indexed keywords

BORTEZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCRISTINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; CANCER INCIDENCE; CANCER INVASION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CYTOGENETICS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE EXTRAMEDULLARY PLASMACYTOMA; MULTIPLE MYELOMA; PATHOGENESIS; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOFT TISSUE TUMOR; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE;

EID: 77955129575     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08157.x     Document Type: Review

References (68)

1. Ali, R., Beksac, M., Ozkalemkas, F., Ozkocaman, V., Ozkan, A., Ozcelik, T. Tunali, A. (2007) Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leukaemia & Lymphoma, 48, 1426 1428.
2. Avet-Loiseau, H., Daviet, A., Brigaudeau, C., Callet-Bauchu, E., Terre, C., Lafage-Pochitaloff, M., Desangles, F., Ramond, S., Talmant, P. Bataille, R. (2001) Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myelome and the Groupe Francais de Cytogenetique Hematologique. Blood, 97, 822 825.
3. Bai, L.Y., Chiu, C.F., Chiang, I.P., Lin, C.Y. Liao, Y.M. (2006) Acalculous cholecystitis mimicking plasma cell leukemia. Annals of Hematology, 85, 487 488.
4. Balleari, E., Ghio, R., Falcone, A. Musto, P. (2004) Possible multiple myeloma dedifferentiation following thalidomide therapy: a report of four cases. Leukaemia & Lymphoma, 45, 735 738.
5. Benson, Jr., D.M. Smith, M.K. (2007) Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leukaemia & Lymphoma, 48, 1423 1425.
6. Bernasconi, C., Castelli, G., Pagnucco, G. Brusamolino, E. (1989) Plasma cell leukemia: a report on 15 patients. European Journal of Haematology. Supplementum, 51, 76 83.
7. Blade, J., Lust, J.A. Kyle, R.A. (1994) Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. Journal of Clinical Oncology, 12, 2398 2404.
8. Blade, J., Kyle, R.A. Greipp, P.R. (1996) Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. British Journal of Haematology, 93, 345 351.
9. Blade, J., Cibeira, M.T., Rosinol, L. de Larrea, C.F. (2009) Extramedullary myeloma. Blood (ASH Annual Meeting Abstracts), 114, SCI-5 Grossman, L. (1977) Plasma cell leukemia following treatment with radiotherapy and melphalan. Canadian Medical Association Journal, 117, 788 789.
10. Butterworth, Jr., C.E., Frommeyer, Jr., W. Riser, Jr., W.H. (1953) Erythrophagocytosis in a case of plasma cell leukemia. Blood, 8, 519 523.
11. Candoni, A., Tiribelli, M. Fanin, R. (2004) Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan. Leukaemia & Lymphoma, 45, 821 824.
12. Chanan-Khan, A.A. Cheson, B.D. (2008) Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology, 26, 1544 1552.
13. Chang, H., Qi, X., Yeung, J., Reece, D., Xu, W. Patterson, B. (2009) Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leukemia Research, 33, 259 262.
14. Colovic, M., Jankovic, G., Suvajdzic, N., Milic, N., Dordevic, V. Jankovic, S. (2008) Thirty patients with primary plasma cell leukemia: a single center experience. Medical Oncology, 25, 154 160.
15. Dawson, M.A., Patil, S. Spencer, A. (2007) Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica, 92, 143 144.
16. Dimopoulos, M.A., Palumbo, A., Delasalle, K.B. Alexanian, R. (1994) Primary plasma cell leukaemia. British Journal of Haematology, 88, 754 759.
17. Finnegan, D.P., Kettle, P., Drake, M., Matthews, C., Alexander, H.D., Popat, R., Cavanagh, J.D., Wachsman, W. Morris, T.C. (2006) Bortezomib is effective in primary plasma cell leukemia. Leukaemia & Lymphoma, 47, 1670 1673.
18. Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P.L., Chesi, M., Davies, F.E., Drach, J., Greipp, P.R., Kirsch, I.R., Kuehl, W.M., Hernandez, J.M., Minvielle, S., Pilarski, L.M., Shaughnessy, Jr., J.D., Stewart, A.K. Avet-Loiseau, H. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research, 64, 1546 1558.
19. Garcia-Sanz, R., Orfao, A., Gonzalez, M., Tabernero, M.D., Blade, J., Moro, M.J., Fernandez-Calvo, J., Sanz, M.A., Perez-Simon, J.A., Rasillo, A. Miguel, J.F. (1999) Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood, 93, 1032 1037.
20. Gawoski, J.M. Ooi, W.W. (2003) Dengue fever mimicking plasma cell leukemia. Archives of Pathology and Laboratory Medicine, 127, 1026 1027.
21. Gemmel, C., Cremer, F.W., Weis, M., Witzens, M., Moldenhauer, G., Koniczek, K.H., Imbach, U., Ho, A.D., Moos, M. Goldschmidt, H. (2002) Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous stem cell transplantation. Annals of Hematology, 81, 119 123.
22. Gozzetti, A., Oliva, S., Gentilini, F., Marchini, E., Petrucci, M.T., Patriarca, F., Petrucci, A., Giaccone, L., Zamagni, E., Genuardi, M., Cavo, M., Palumbo, A., Rossi, D., Offidani, M., Cerase, A., De Paoli, L., Floridia, M., Mele, G., Galli, M., Beretta, S., Di Raimondo, F., Vallone, R. Lauria, F. (2009) Central Nervous System and Intracranial Myeloma: a Retrospective Italian Multicenter Study. Blood (ASH Annual Meeting Abstracts), 114, 1882.
23. Han, X., Kilfoy, B., Zheng, T., Holford, T.R., Zhu, C., Zhu, Y. Zhang, Y. (2008) Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes and Control, 19, 841 858.
24. Hjorth-Hansen, H., Waage, A. Borset, M. (1999) Interleukin-15 blocks apoptosis and induces proliferation of the human myeloma cell line OH-2 and freshly isolated myeloma cells. British Journal of Haematology, 106, 28 34.
25. Hosono, N., Yamauchi, T., Nakamura, T., Yamashita, T. Ueda, T. (2008) [Plasma cell leukemia induced to complete remission with negative minimal residual disease by qualitative PCR analysis after hyper-CVAD and high-dose melphalan followed by autologous peripheral blood stem cell transplantation]. Gan To Kagaku Ryoho, 35, 533 537.
26. Iseki, T., Iwasa, S., Okuda, K., Kanazawa, S., Kondo, H. Yonemitsu, H. (1987) [IgA-lambda plasma cell leukemia with gum infiltration and pleural effusion]. Rinsho Ketsueki, 28, 428 433.
27. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. Thun, M.J. (2008) Cancer statistics. CA: A Cancer Journal for Clinicians, 58, 71 96.
28. Jimenez-Zepeda, V.H. Dominguez, V.J. (2006) Plasma cell leukemia: a rare condition. Annals of Hematology, 85, 263 267.
29. Johnston, R.E. Abdalla, S.H. (2002) Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia. Leukaemia & Lymphoma, 43, 351 354.
30. Katodritou, E., Verrou, E., Gastari, V., Hadjiaggelidou, C., Terpos, E. Zervas, K. (2008) Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leukemia Research, 32, 1153 1156.
31. Katodritou, E., Gastari, V., Verrou, E., Hadjiaggelidou, C., Varthaliti, M., Georgiadou, S., Laschos, K., Xirou, P., Yiannaki, E., Constantinou, N., Markala, D. Zervas, K. (2009) Extramedullary (EMP) relapse in unusual locations in multiple myeloma: is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome? Leukemia Research, 33, 1137 1140.
32. Kawano, F., Tsukamoto, A., Satoh, M., Sanada, I., Shido, T., Miura, K., Murakami, T., Kaneko, H., Takeya, M. Matsuzaki, H. (1991) [Non-secretory primary plasma cell leukemia with hyperammonemia]. Rinsho Ketsueki, 32, 399 403.
33. Klug, S., Holtermann, F. Fritsch, H. (1992) [IgG-lambda-type multiple myeloma with plasma-cell pericardial effusion and terminal plasma-cell leukemia]. Deutsche Medizinische Wochenschrift, 117, 900 904.
34. Korte, W., Jost, C., Cogliatti, S., Hess, U. Cerny, T. (1999) Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Annals of Oncology, 10, 1249 1250.
35. Kumar, S.K., Rajkumar, S.V., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Zeldenrust, S.R., Dingli, D., Russell, S.J., Lust, J.A., Greipp, P.R., Kyle, R.A. Gertz, M.A. (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood, 111, 2516 2520.
36. Manochakian, R., Miller, K.C., Coignet, J.-G., Padmanabhan, S., Musial, L., DePaolo, D. Chanan-Khan, A.A. (2006) Incidence, clinical presentation and outcome of secondary multiple extramedullary plasmacytomas: experience at Roswell Park Cancer Institute. ASH Annual Meeting Abstracts, 108, 5057.
37. Minauchi, K., Fujie, T., Matsubara, N., Kasahara, H., Ogura, Y., Tamura, M., Yamane, Y., Tanaka, M. Taneichi, K. (2004) [Primary plasma cell leukemia (IgD-lambda) with hyperammonemia]. Nippon Naika Gakkai Zasshi, 93, 139 141.
38. Minnema, M.C., van de Donk, N.W., Zweegman, S., Hegenbart, U., Schonland, S., Raymakers, R., Zijlmans, J.M., Kersten, M.J., Bos, G.M. Lokhorst, H.M. (2008) Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplantation, 41, 779 784.
39. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C., Hideshima, T. Anderson, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377 2380.
40. Murthy, V., Mwirigi, A., Ward, S. Rassam, S.M.B. (2009) Rapid and excellent response to hyper CVAD, particularly with thalidomide, in plasma cell leukaemia and long term remissions following allogeneic stem cell transplantation. ASH Annual Meeting Abstracts, 114, 4963.
41. Musto, P., Rossini, F., Gay, F., Pitini, V., Guglielmelli, T., D'Arena, G., Ferrara, F., Filardi, N., Guariglia, R. Palumbo, A. GISMM, GISL, & GIMEMA Cooperative Group 2007) Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer, 109, 2285 2290.
42. Musto, P., Pietrantuono, G., Guariglia, R., Villani, O., Martorelli, M.C., D'Auria, F., Zonno, A. Lerose, R. (2008) Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leukemia Research, 32, 1637 1638.
43. Nakahashi, E., Kuribayashi, N., Tsuji, N., Kawaguchi, T., Hata, H., Matsuzaki, H., Shimizu, K. Takatsuki, K. (1994) [Primary plasma cell leukemia complicated with high-output cardiac failure and hyperammonemia]. Rinsho Ketsueki, 35, 756 760.
44. Noel, P. Kyle, R.A. (1987) Plasma cell leukemia: an evaluation of response to therapy. American Journal of Medicine, 83, 1062 1068.
45. Oka, S., Yokote, T., Akioka, T., Hara, S., Yamano, T., Tsuji, M. Hanafusa, T. (2006) Successful treatment of multi-agent chemotherapy with rituximab for IgM plasma cell leukemia. Leukemia Research, 30, 1581 1583.
46. Pagano, L., Valentini, C.G., De Stefano, V., Venditti, A., Visani, G., Petrucci, M.T., Candoni, A., Specchia, G., Visco, C., Pogliani, E.M., Ferrara, F., Galieni, P., Gozzetti, A., Avvisati, G., Leone, G., Musto, P. Pulsoni, A. (2009) Primary plasma cell leukemia: results of a retrospective Italian multicentric survey. ASH Annual Meeting Abstracts, 114, 2885.
47. Peijing, Q., Yan, X., Yafei, W., Dehui, Z., Zengjun, L., Junyuan, Q., Yaozhong, Z. Lugui, Q. (2009) A retrospective analysis of thirty-one cases of plasma cell leukemia from a single center in China. Acta Haematologica, 121, 47 51.
48. Pellat-Deceunynck, C., Barille, S., Jego, G., Puthier, D., Robillard, N., Pineau, D., Rapp, M.J., Harousseau, J.L., Amiot, M. Bataille, R. (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia, 12, 1977 1982.
49. Perez-Andres, M., Almeida, J., Martin-Ayuso, M., Moro, M.J., Martin-Nunez, G., Galende, J., Borrego, D., Rodriguez, M.J., Ortega, F., Hernandez, J., Moreno, I., Dominguez, M., Mateo, G., San Miguel, J.F. Orfao, A. (2005) Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia, 19, 449 455.
50. Perez-Simon, J.A., Sureda, A., Fernandez-Aviles, F., Sampol, A., Cabrera, J.R., Caballero, D., Martino, R., Petit, J., Tomas, J.F., Moraleda, J.M., Alegre, A., Canizo, C., Brunet, S., Rosinol, L., Lahuerta, J., Diez-Martin, J.L., Leon, A., Garcia, A., Vazquez, L., Sierra, J. San Miguel, J.F. (2006) Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia, 20, 542 545.
51. Petrucci, M.T., Martini, V., Levi, A., Gallucci, C., Palumbo, G., Del Bianco, P., Torromeo, C. Foa, R. (2007) Thalidomide does not modify the prognosis of plasma cell leukemia patients: experience of a single center. Leukaemia & Lymphoma, 48, 180 182.
52. Pope, B., Brown, R., Luo, X.F., Gibson, J. Joshua, D. (1997) Disease progression in patients with multiple myeloma is associated with a concurrent alteration in the expression of both oncogenes and tumour suppressor genes and can be monitored by the oncoprotein phenotype. Leukaemia & Lymphoma, 25, 545 554.
53. Rawstron, A., Barrans, S., Blythe, D., Davies, F., English, A., Pratt, G., Child, A., Morgan, G. Jack, A. (1999) Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression. British Journal Haematology, 104, 138 143.
54. Roodman, G.D. (2002) Role of the bone marrow microenvironment in multiple myeloma. Journal of Bone and Mineral Research, 17, 1921 1925.
55. Saccaro, S., Fonseca, R., Veillon, D.M., Cotelingam, J., Nordberg, M.L., Bredeson, C., Glass, J. Munker, R. (2005) Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. American Journal of Hematology, 78, 288 294.
56. Sahara, N., Takeshita, A., Shigeno, K., Fujisawa, S., Takeshita, K., Naito, K., Ihara, M., Ono, T., Tamashima, S., Nara, K., Ohnishi, K. Ohno, R. (2002) Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. British Journal of Haematology, 117, 882 885.
57. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906 917.
58. Sher, T., Miller, K.C., Lee, K. Chanan-Khan, A. (2009) Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clinical Lymphoma & Myeloma, 9, 328 330.
59. Shtalrid, M., Shvidel, L. Vorst, E. (2003) Polyclonal reactive peripheral blood plasmacytosis mimicking plasma cell leukemia in a patient with Staphylococcal sepsis. Leukaemia & Lymphoma, 44, 379 380.
60. Skopelitou, A., Hadjiyannakis, M., Tsenga, A., Theocharis, S., Alexopoulou, V., Kittas, C. Agnantis, N. (1993) Expression of C-myc p62 oncoprotein in multiple myeloma: an immunohistochemical study of 180 cases. Anticancer Research, 13, 1091 1095.
61. Tiedemann, R.E., Gonzalez-Paz, N., Kyle, R.A., Santana-Davila, R., Price-Troska, T., Van Wier, S.A., Chng, W.J., Ketterling, R.P., Gertz, M.A., Henderson, K., Greipp, P.R., Dispenzieri, A., Lacy, M.Q., Rajkumar, S.V., Bergsagel, P.L., Stewart, A.K. Fonseca, R. (2008) Genetic aberrations and survival in plasma cell leukemia. Leukemia, 22, 1044 1052.
62. Tricot, G. (2000) New insights into role of microenvironment in multiple myeloma. Lancet, 355, 248 250.
63. Turhal, N., Henehan, M.D. Kaplan, K.L. (1998) Multiple myeloma: a patient with unusual features including intracranial and meningeal involvement, testicular involvement, organomegaly, and plasma cell leukemia. American Journal of Hematology, 57, 51 56.
64. Varettoni, M., Corso, A., Pica, G., Mangiacavalli, S., Pascutto, C. Lazzarino, M. (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Annals of Oncology, 21, 325 330.
65. Vela-Ojeda, J., Garcia-Ruiz Esparza, M.A., Rosas-Cabral, A., Padilla-Gonzalez, Y., Garcia-Chavez, J., Tripp-Villanueva, F., Sanchez-Cortes, E., Ayala-Sanchez, M., Garcia-Leon, L.D., Montiel-Cervantes, L. Rubio-Borja, M.E. (2002) Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. Annals of Hematology, 81, 362 367.
66. Xu, W., Li, J.Y., Fan, L., Chen, L.J., Qiu, H.R., Qiu, H.X. Lu, H. (2009) Molecular cytogenetic aberrations in 21 Chinese patients with plasma cell leukemia. International Journal of Laboratory Hematology, 31, 338 343.
67. Yamagata, N., Shimazaki, C., Goto, H., Hirata, T., Ashihara, E., Oku, N., Inaba, T., Fujita, N. Nakagawa, M. (1994) IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha. American Journal of Hematology, 45, 262 264.
68. Yeh, K.H., Lin, M.T., Tang, J.L., Yang, C.H., Tsay, W. Chen, Y.C. (1995) Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes. British Journal of Haematology, 89, 914 916.